Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
Thomas Powles(Queen Mary University of London), Christopher J. Sweeney(The University of Adelaide), Silke Gillessen(Institute of Oncology Research), Begoña Mellado(Hospital Clínic de Barcelona), Grozdana Rasuo(Roche (Switzerland)), Sanjeev Mariathasan(Kaiser Permanente San Francisco Medical Center), Nobuaki Matsubara(National Cancer Center Hospital East), Josep M. Piulats(Institut Català d'Ornitologia), B. Yа. Alekseev(P.A. Hertzen Moscow Oncology Research Institute), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), Gary L. Buchschacher(Kaiser Permanente), Asim Datye(Roche (Switzerland)), Kobe Yuen(La Roche College), Piotr J. Wysocki(Jagiellonian University), Jennifer Doss(Duke University), Edward E. Kadel, Patrick Williams(The University of Texas MD Anderson Cancer Center), Bogusława Karaszewska, Charles G. Drake(Columbia University Irving Medical Center), Karim Fizazi(Université de Lille)
Cited by 241
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k